Stockscreener 앱 받기
3.295
2.33%
0.075
시장 영업 전:
3.30
0.005
+0.15%
Elicio Therapeutics Inc 주식(ELTX)의 최신 뉴스
Elicio Therapeutics Prices $15 Million Registered Direct Offering at $3.43; Signs Purchase, Placement Pacts - TradingView
Elicio Therapeutics (ELTX) prices $15M registered direct equity offering - Stock Titan
Elicio Therapeutics Prices $15 Million Direct Offering - marketscreener.com
Elicio locks in $15M to fund Phase 1 KRAS cancer trial - Stock Titan
Elicio Therapeutics prices $15M stock offering to fund cancer immunotherapy trials. - Pluang
Elicio Therapeutics raises $15M in registered direct offering - Investing.com
Elicio Therapeutics raises $15M in registered direct offering By Investing.com - Investing.com Nigeria
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering - GlobeNewswire
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering - GlobeNewswire Inc.
Price to book forward of Elicio Therapeutics, Inc. – NASDAQ:ELTX - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elicio Therapeutics, Inc. (ELTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc.ELTX - FinancialContent
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elicio Therap - The National Law Review
Elicio Therapeutics, Inc.(NasdaqCM: ELTX) added to Russell 2000 Index - marketscreener.com
Elicio Therapeutics, Inc.(NasdaqCM: ELTX) added to Russell 2500 Growth Benchmark - marketscreener.com
Elicio Therapeutics, Inc.(NasdaqCM:ELTX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Elicio Therapeutics, Inc. (ELTX) Investigation: Bronstein, Gewirt - The National Law Review
Elicio Therapeutics Joins Russell 2000 and 3000 Indexes (ELTX) - GuruFocus
Elicio Therapeutics added to Russell 2000 and 3000 indexes - Investing.com
Elicio Therapeutics, Inc.(NasdaqCM:ELTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Elicio Therapeutics added to Russell 2000 and 3000 indexes By Investing.com - Investing.com Canada
Elicio Therapeutics joins Russell indexes after annual reconstitution - Stock Titan
Elicio Therapeutics, Inc.(NasdaqCM: ELTX) added to Russell 2000 Growth Benchmark - marketscreener.com
Elicio Therapeutics, Inc.(NasdaqCM: ELTX) added to Russell 3000E Growth Benchmark - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elicio Therapeutics, Inc. (ELTX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2026-06-28 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elicio Therapeutics, Inc. (ELTX) and Encourages Stockholders to Learn More About the Investigation | NDAQ:ELTX | Press Release - Stockhouse
Elicio Therapeutics, Inc Actuals & Estimates (NASDAQ:ELTX) - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages Elicio Therapeutics, Inc. (ELTX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Elicio Therapeutics - The National Law Review
ELTX Forecast — Price Target — Prediction for 2027 - TradingView
Elicio Therapeutics, Inc Actuals & Estimates (LSX:A3CY4J) - TradingView
ELTX Investors Have Opportunity to Join Elicio Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - The National Law Review
A3CY4J Forecast — Price Target — Prediction for 2027 - TradingView
Elicio Therapeutics (ELTX) outlines ELI-002 7P combo trial plan in metastatic pancreatic cancer - Stock Titan
ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints - Stocktwits
Elicio Therapeutics (ELTX) Drops 4.14% as Bearish Momentum Tests Key SupportFactor Rotation - dars.gov.et
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio ... - Caledonian Record
Elicio Therapeutics Inc (ELTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
H.C. Wainwright reiterates Elicio Therapeutics stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Elicio Therapeutics Inc (ELTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Elicio Therapeutics (ELTX) Corporate presentation Summary - Quartr
Elicio Therapeutics (ELTX) Registration Filing Summary - Quartr
Elicio Therapeutics Inc. (NASDAQ: ELTX) Stock Price, News & Analysis - Kalkine
Ladenburg Thalmann starts Elicio Therapeutics stock at buy By Investing.com - Investing.com Australia
Ladenburg Thalmann Initiates Elicio Therapeutics(ELTX.US) With Buy Rating, Announces Target Price $12 - Moomoo
Ladenburg Thalmann starts Elicio Therapeutics stock at buy - Investing.com UK
Top Biotech Gainers: QURE Rallies On AMT-130 Update, LNAI On Track, FTH Eyes Q4 Data, ELTX On Watch - RTTNews
Elicio Therapeutics Inc (ELTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Elicio Therapeutics Inc (ELTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Elicio Therapeutics Inc (ELTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Elicio Therapeutics Rebounds as Investors Refocus on Subgroup Data and a Revised Phase 3 Plan - Moomoo
Elicio Therapeutics rebounds as investors refocus on subgroup data and a revised Phase 3 plan - Quiver Quantitative
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Elicio Therapeutics Inc (ELTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Elicio Therapeutics Inc (ELTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Elicio Therapeutics Inc (ELTX) Institutional Confidence - TradingKey
Elicio Therapeutics Inc (ELTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
0.05%
0.74%
자본화:
|
볼륨(24시간):